A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates

Key Points

• The mechanistic pharmacokinetic-pharmacodynamic model predicts drug efficacy based on conjugate characteristics, enabling better treatments.
• Predictions from the model highlight improved targeting of degrader-antibody conjugates, essential for developing novel therapies.
• Observational analysis on drug interactions through a comprehensive model shows distinct advantages over traditional methods.
• Improved understanding of drug behavior may lead to more effective cancer therapies, though further validation is needed.